Haloperidol treatment after high-dose methamphetamine administration is excitotoxic to GABA cells in the substantia nigra pars reticulata

Theo Hatzipetros, Jamie G. Raudensky, Jean Jacques Soghomonian, Bryan Yamamoto

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The therapeutic management of methamphetamine (METH)-induced psychoses often involves treatment with the typical antipsychotic drug and dopamine D 2 receptor antagonist haloperidol. We report here that subchronic haloperidol administration after a high-dose regimen of METH produces a heretofore unrecognized toxicity to GABAergic cells, as reflected by GAD67 mRNA expression histochemistry, in the rat substantia nigra pars reticulata (SNr) through an acute and persistent augmentation of glutamate release, NMDA receptor activation, and DNA fragmentation. The dopaminergic cells in the substantia nigra pars compacta were unaffected by METH or haloperidol alone or the combination of METH and haloperidol. These findings suggest that the current therapeutic management of METH-induced psychoses with haloperidolmaybe contraindicated because of a resultant GABAergic cell death in the SNr, which may predispose some individuals to the development of hyperkinetic movement disorders and seizures.

Original languageEnglish (US)
Pages (from-to)5895-5902
Number of pages8
JournalJournal of Neuroscience
Volume27
Issue number22
DOIs
StatePublished - May 30 2007
Externally publishedYes

Fingerprint

GABAergic Neurons
Methamphetamine
Haloperidol
Psychotic Disorders
Hyperkinesis
Movement Disorders
DNA Fragmentation
N-Methyl-D-Aspartate Receptors
Antipsychotic Agents
Glutamic Acid
Dopamine
Seizures
Cell Death
Pars Reticulata
Messenger RNA
Therapeutics

Keywords

  • Antipsychotics
  • Basal ganglia
  • Dopamine
  • Glutamate
  • Microdialysis
  • Neurodegeneration

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Haloperidol treatment after high-dose methamphetamine administration is excitotoxic to GABA cells in the substantia nigra pars reticulata. / Hatzipetros, Theo; Raudensky, Jamie G.; Soghomonian, Jean Jacques; Yamamoto, Bryan.

In: Journal of Neuroscience, Vol. 27, No. 22, 30.05.2007, p. 5895-5902.

Research output: Contribution to journalArticle

@article{83055179c2a64a138d2f437e76a1994c,
title = "Haloperidol treatment after high-dose methamphetamine administration is excitotoxic to GABA cells in the substantia nigra pars reticulata",
abstract = "The therapeutic management of methamphetamine (METH)-induced psychoses often involves treatment with the typical antipsychotic drug and dopamine D 2 receptor antagonist haloperidol. We report here that subchronic haloperidol administration after a high-dose regimen of METH produces a heretofore unrecognized toxicity to GABAergic cells, as reflected by GAD67 mRNA expression histochemistry, in the rat substantia nigra pars reticulata (SNr) through an acute and persistent augmentation of glutamate release, NMDA receptor activation, and DNA fragmentation. The dopaminergic cells in the substantia nigra pars compacta were unaffected by METH or haloperidol alone or the combination of METH and haloperidol. These findings suggest that the current therapeutic management of METH-induced psychoses with haloperidolmaybe contraindicated because of a resultant GABAergic cell death in the SNr, which may predispose some individuals to the development of hyperkinetic movement disorders and seizures.",
keywords = "Antipsychotics, Basal ganglia, Dopamine, Glutamate, Microdialysis, Neurodegeneration",
author = "Theo Hatzipetros and Raudensky, {Jamie G.} and Soghomonian, {Jean Jacques} and Bryan Yamamoto",
year = "2007",
month = "5",
day = "30",
doi = "10.1523/JNEUROSCI.5260-06.2007",
language = "English (US)",
volume = "27",
pages = "5895--5902",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "22",

}

TY - JOUR

T1 - Haloperidol treatment after high-dose methamphetamine administration is excitotoxic to GABA cells in the substantia nigra pars reticulata

AU - Hatzipetros, Theo

AU - Raudensky, Jamie G.

AU - Soghomonian, Jean Jacques

AU - Yamamoto, Bryan

PY - 2007/5/30

Y1 - 2007/5/30

N2 - The therapeutic management of methamphetamine (METH)-induced psychoses often involves treatment with the typical antipsychotic drug and dopamine D 2 receptor antagonist haloperidol. We report here that subchronic haloperidol administration after a high-dose regimen of METH produces a heretofore unrecognized toxicity to GABAergic cells, as reflected by GAD67 mRNA expression histochemistry, in the rat substantia nigra pars reticulata (SNr) through an acute and persistent augmentation of glutamate release, NMDA receptor activation, and DNA fragmentation. The dopaminergic cells in the substantia nigra pars compacta were unaffected by METH or haloperidol alone or the combination of METH and haloperidol. These findings suggest that the current therapeutic management of METH-induced psychoses with haloperidolmaybe contraindicated because of a resultant GABAergic cell death in the SNr, which may predispose some individuals to the development of hyperkinetic movement disorders and seizures.

AB - The therapeutic management of methamphetamine (METH)-induced psychoses often involves treatment with the typical antipsychotic drug and dopamine D 2 receptor antagonist haloperidol. We report here that subchronic haloperidol administration after a high-dose regimen of METH produces a heretofore unrecognized toxicity to GABAergic cells, as reflected by GAD67 mRNA expression histochemistry, in the rat substantia nigra pars reticulata (SNr) through an acute and persistent augmentation of glutamate release, NMDA receptor activation, and DNA fragmentation. The dopaminergic cells in the substantia nigra pars compacta were unaffected by METH or haloperidol alone or the combination of METH and haloperidol. These findings suggest that the current therapeutic management of METH-induced psychoses with haloperidolmaybe contraindicated because of a resultant GABAergic cell death in the SNr, which may predispose some individuals to the development of hyperkinetic movement disorders and seizures.

KW - Antipsychotics

KW - Basal ganglia

KW - Dopamine

KW - Glutamate

KW - Microdialysis

KW - Neurodegeneration

UR - http://www.scopus.com/inward/record.url?scp=34249791161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249791161&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.5260-06.2007

DO - 10.1523/JNEUROSCI.5260-06.2007

M3 - Article

C2 - 17537960

AN - SCOPUS:34249791161

VL - 27

SP - 5895

EP - 5902

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 22

ER -